Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01428310 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke
A Phase 1 study, sponsored by Rock Creek Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 109
- Enrollment target
NCT01428310 is a Phase 1 study that has completed, run by Rock Creek Pharmaceuticals. The registered enrollment target is 109 participants.
The verdict
NCT01428310, a Phase 1 study, has completed, sponsored by Rock Creek Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 109 participants
- Enrollment target
Study Summary
This study will consist of 2 phases. Phase 1 will be a one day crossover study to see the effects of study product on a smoker's desire to smoke, measured by changes in scores on questionnaires given over time. Phase 2 will be a two-week extension, in which subjects will self-administer the study product and visit the study site for assessment of desire to smoke and collection of samples for the evaluation of smoking-related biomarkers.
Interventions
- DIETARY_SUPPLEMENT Anatabloc(TM)
- DIETARY_SUPPLEMENT CigRx(R)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2011-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01428310
The ClinicalTrials.gov registry entry for NCT01428310 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rock Creek Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Anatabloc(TM) is the first listed.
NCT01428310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01428310 about?
NCT01428310 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke". This study will consist of 2 phases. Phase 1 will be a one day crossover study to see the effects of study product on a smoker's desire to smoke, measured by changes in scores on questionnaires given over time. Phase 2 will be a two-week extension, in which subjects will self-administer the study pr...
What is the current status of trial NCT01428310?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 109 participants. The study started on 2011-09. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01428310?
The interventions under investigation include: Anatabloc(TM) (DIETARY_SUPPLEMENT), CigRx(R) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01428310?
This trial is sponsored by Rock Creek Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.